LungLifeAI Logo

Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Description of the Business

Names of the directors, biographical details and responsibilities

Corporate governance

Country of incorporation / operation

Shareholder Information

  • Other Exchanges and Trading Platforms
  • Shares in Issue
  • Significant Shareholdings
  • Director Shareholdings
  • Shares Not in Public Hands
  • Restrictions in Transfer of AIM Securities
  • UK City Code on Takeovers and Mergers

Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

May 11, 2022

Result of Annual General Meeting

LungLife AI, Inc. (the “Company” or “LungLife”) Result of Annual General Meeting LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces that at the Annual General Meeting, held at Investec Bank PLC, 30 Gresham St, London, EC2V 7QP earlier today, all 8 resolutions put to members were passed on a […]
• Read More
May 9, 2022

AGM dial in details (09.05.22)

The Annual General Meeting of LungLife AI,Inc. the “Company”) to be held at 2:00 p.m. BST on 11 May 2022 at Investec Bank plc, 30 Gresham Street, London, EC2V 7QP, United Kingdom (including any adjournment or postponement thereof, the “AGM”). Stockholders will be able to listen live to the AGM by accessing the below Microsoft […]
• Read More
LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.
crosschevron-down